Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours

British Journal of Clinical Pharmacology

Volumn 71, Issue 3, 2011, Pages 437-444

  Gusella, Milena ^a   Pasini, Felice ^b   Bolzonella, Caterina ^a   Meneghetti, Silvia ^a   Barile, Carmen ^b   Bononi, Antonio ^b   Toso, Silvia ^b   Menon, Daniela ^b   Crepaldi, Giorgio ^b   Modena, Yasmina ^b   Stievano, Laura ^c   Padrini, Roberto ^d  

^a Laboratorio di Farmacologia e Biologia Molecolare   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cytidine deaminase; Deoxycytidine kinase; Gemcitabine; Nucleoside transporter; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CYTIDINE DEAMINASE; DIFLUORODEOXYURINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; GENOMIC DNA; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG CLEARANCE; EX VIVO STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CYTIDINE DEAMINASE; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 79251632402     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03838.x     Document Type: Article

References (30)

1. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41: 77-88.
2. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
3. Damaraju VJ, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22: 7524-36.
4. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrel ER. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics 2006; 16: 315-20.
5. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512-9.
6. Ruiz Van Haperen R, Veerman G, Braakuis BJ, Vermorken JB, Boven E, Leyva A, Peters GJ. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 1993; 29A: 2132-7.
7. Skeith KJ, Wefuran J, Oswald R, Davis P. Serum cytidine deaminase as a measure of disease activity in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1993; 20: 1309-15.
8. 3. Biochim Biophys Acta 1996; 1312: 99-104.
9. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81.
10. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.
11. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620-4.
12. Paira S, Roverano S, Rillo O, Barrionuevo A, Mahieu S, Millen N. Cytidine deaminase in polymyalgia rheumatica and elderly onset rheumatoid arthritis. Clin Rheumatol 2005; 24: 460-3.
13. Veltkampt SA, Beijnen JH, Schellens JHM. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008; 13: 261-76.
14. Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 2001; 12: 1553-9.
15. Lanz C, Früh M, Thormann W, Cerny T, Lauter BH. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. J Sep Sci 2007; 30: 1811-20.
16. Grunewald R, Kantarijan H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukaemia: a phase I clinical trial, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-13.
17. Bouffard DY, Laliberté J, Momparler RL. Kinetic studies on 2', 2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993; 45: 1857-61.
18. Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003; 479: 269-81.
19. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1809-R1822.
20. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 2001; 280: 951-9.
21. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-7.
22. Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, Togo S, Danenberg PV, Shimada H. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 2007; 17: 1201-5.
23. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349-57.
24. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-61.
25. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-9.
26. Farrel JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-95.
27. Giovanetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-35.
28. Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol 2007; 65: 326-33.
29. Gan HK, Mitchell PL, Galettis P, Davis ID, Cebon J, de Souza P, Links M. A phase 1 and pharmacokinetics study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemother Pharmacol 2006; 58: 157-64.
30. Grimison P, Galettis P, Manners S, Jelinek M, Metharom E, de Souza PL, Liauw W, Links MJ. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007; 25: 5704-9.